

Incidence of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Illness in Infants in Low- and Middle-Income Regions During the Coronavirus Disease 2019 Pandemic

Samantha Fry,¹ Kulkanya Choekphaibulkit,² Sridevi Pallem,³ Ouzama Henry,^{4,a} Yongjia Pu,^{4,b} Agnes Akawung,³ Joon Hyung Kim,⁴ Emad Yanni,⁴ Antonella Nadia Tullio,^{4,c} Linda Aurpibul,^{5,6} Christine Mui Fong Lee,⁶ Ana Ceballos,⁷ Khalequ Zaman,⁸ Ivonne Abadía de Regalado,⁹ Khatija Ahmed,^{10,11} Diana Andrea Arias Fernandez,¹² Sri Wahyu Taher,¹³ Juliana Caccavo,¹⁴ Conrado Milani Coutinho,¹⁵ Ulises D'Andrea Nores,⁷ Tirza De León,¹⁶ Emily Christine D'Silva,¹⁷ Mara De Bernardi,¹⁴ Pablo Dieser,⁷ Andrea Falaschi,^{18,19} Clara del Carmen Flores Acosta,²⁰ Angela Gentile,²¹ Ik Hui Teo,²² Sheena Kotze,²³ Eduardo López-Medina,^{24,25,6} Ruben Luca,²⁶ Maria Florencia Lucion,²¹ Jacinto Blas III V. Mantaring,²⁷ Bladimir Marín,¹² Malahleha Moelo,^{10,d} Marisa Márcia Mussi-Pinhata,²⁸ Jorge Pinto,²⁹ Thanayawee Puthanakit,³⁰ Osvaldo Reyes,^{31,32,33} Maria Fernanda Roa,³⁴ Maria Teresa Rodriguez Brieschke,¹⁴ Camilo Enrique Rodriguez,^{35,36} Juan Nicolas Rodriguez Niño,³⁵ Alexandre Vargas Schwarzbald,³⁷ Alexandra Sierra Garcia,^{24,25} Lavitha Sivapatham,³⁸ Ruey Soon,³⁹ Juan Carlos Tinoco,⁴⁰ Jesús Arnulfo Velásquez Penagos,⁴¹ and Gaël Dos Santos^{42,6}

¹Department of Paediatrics and Child Health, Family Centre for Research with Ubuntu, Stellenbosch University, Cape Town, South Africa, ²Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ³Keyrus Life Science c/o GSK, Wavre, Belgium, ⁴GSK, Rockville, Maryland, USA, ⁵Research Institute for Health Science, Chiang Mai University, Chiang Mai, Thailand, ⁶Department of Obstetrics and Gynaecology, Sarawak General Hospital, Kuching, Malaysia, ⁷Instituto Médico Río Cuarto, Río Cuarto, Córdoba, Argentina, ⁸International Centre for Diarrhoeal Disease Research (icddr, b), Dhaka, Bangladesh, ⁹Policentro de Salud de Juan Díaz, Juan Díaz, Panama, ¹⁰Setshaba Research Centre, Soshanguve, South Africa, ¹¹Faculty of Health Sciences, Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa, ¹²Hospital San José, Bogotá, Colombia, ¹³Simpang Kuala Health Clinic, Alor Setar, Malaysia, ¹⁴Donación Francisco Santojanni Hospital, Buenos Aires, Argentina, ¹⁵Department of Gynecology and Obstetrics, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil, ¹⁶Maternity Hospital José Domingo De Obaldía, San Pablo Viejo, Panama, ¹⁷Department of Obstetrics and Gynecology, Ampang Hospital, Selangor, Malaysia, ¹⁸Dr Ramon Carrillo Hospital, Mendoza, Argentina, ¹⁹Dr Diego Paroissien Hospital, Mendoza, Argentina, ²⁰Dr José E. González University Hospital, Autonomous University of Nuevo León, Monterrey, Mexico, ²¹Epidemiology Department, Hospital de Niños Dr Ricardo Gutiérrez, Buenos Aires, Argentina, ²²Hospital Ampang, Kuala Lumpur, Malaysia, ²³Synexus Stanza Clinical Research Centre, Pretoria, South Africa, ²⁴Centro de Estudios en Infectología Pediátrica, Department of Pediatrics, Universidad del Valle, Valle del Cauca, Colombia, ²⁵Clinica Imbanaco, Grupo Quiron Salud, Cali, Colombia, ²⁶Hospital F. F. Santojanni C1407, Buenos Aires, Argentina, ²⁷Department of Clinical Epidemiology, University of the Philippines, Philippine General Hospital, Manila, Philippines, ²⁸Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil, ²⁹Department of Pediatrics, Federal University of Minas Gerais, Belo Horizonte, Brazil, ³⁰Department of Pediatrics and Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³¹Santo Tomás Hospital, Panama City, Panama, ³²Centro de Vacunación Internacional S.A., La Chorrera, Panama, ³³Member of the Sistema Nacional de Investigadores (SNI), Panama City, Panama, ³⁴Department of Pediatrics, University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ³⁵Department of Gynecology and Obstetrics, University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ³⁶School of Medicine, University of the Andes, Bogotá, Colombia, ³⁷Hospital Universitário de Santa Maria, Centro de Pesquisa Clínica, Universidade Federal de Santa Maria, Santa Maria, Brazil, ³⁸Department of Obstetrics and Gynecology, Ampang Hospital, Ampang, Malaysia, ³⁹Department of Obstetrics and Gynecology, Sabah Women's and Children's Hospital, Kota Kinabalu, Malaysia, ⁴⁰General Hospital of Durango, Durango, Mexico, ⁴¹San Vicente Fundación University Hospital, Medellín, Colombia, and ⁴²GSK, Wavre, Belgium

Background. Incidence data of respiratory syncytial virus–associated lower respiratory tract illness (RSV-LRTI) are sparse in low- and middle-income countries (LMICs). We estimated RSV-LRTI incidence rates (IRs) in infants in LMICs using World Health Organization case definitions.

Methods. This prospective cohort study, conducted in 10 LMICs from May 2019 to October 2021 (largely overlapping with the coronavirus disease 2019 [COVID-19] pandemic), followed infants born to women with low-risk pregnancies for 1 year from birth using active and passive surveillance to detect potential LRTIs, and quantitative reverse-transcription polymerase chain reaction on nasal swabs to detect RSV.

Results. Among 2094 infants, 32 (1.5%) experienced an RSV-LRTI (8 during their first 6 months of life, 24 thereafter). Seventeen (0.8%) infants had severe RSV-LRTI and 168 (8.0%) had all-cause LRTI. IRs (95% confidence intervals [CIs]) of first RSV-LRTI episode were 1.0 (0.3–2.3), 0.8 (0.3–1.5), and 1.6 (1.1–2.2) per 100 person-years for infants aged 0–2, 0–5, and 0–11 months, respectively. IRs (95% CIs) of the first all-cause LRTI episode were 10.7 (8.1–14.0), 11.7 (9.6–14.0), and 8.7 (7.5–10.2) per 100 person-years, respectively. IRs varied by country (RSV-LRTI: 0.0–8.3, all-cause LRTI: 0.0–49.6 per 100 person-years for 0- to 11-month-olds).

Conclusions. RSV-LRTI IRs in infants in this study were relatively low, likely due to reduced viral circulation caused by COVID-19–related nonpharmaceutical interventions.

Clinical Trials Registration. NCT03614676.

Received 07 April 2023; editorial decision 27 October 2023; published online 1 December 2023

Correspondence: Gaël Dos Santos, PhD, GSK, Avenue Fleming 20, 1300 Wavre, Belgium (gael.x.dos-santos@gsk.com).

^aPresent affiliation: Dynavax Technologies, Emeryville, California, USA.

^bPresent affiliation: AbbVie, North Chicago, Illinois 60064, USA.

^cPresent affiliation: AstraZeneca, Gaithersburg, Maryland, USA.

^dPresent affiliation: Synergy Biomed Research Institute, East London, South Africa.

Open Forum Infectious Diseases®

© GSK 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. <https://doi.org/10.1093/ofid/ofad553>

Keywords. epidemiology; incidence; infants; lower respiratory tract illness; respiratory syncytial virus

Lay summary. Respiratory syncytial virus (RSV) can cause serious illnesses, such as pneumonia, especially in infants and young children in low- and middle-income countries. We evaluated the frequency of RSV-associated lower respiratory tract illness (RSV-LRTI) in infants in these countries. Our study largely overlapped with the COVID-19 pandemic, when measures like lockdowns, physical distancing, and masks strongly reduced the spread of respiratory viruses. We followed 2094 infants in 10 low- and middle-income countries in Asia, Africa, and South America from birth to their first birthday. In total, 168 infants had at least one LRTI episode in their first year of life, of whom 32 (19%) had RSV-LRTI; 17 RSV-LRTIs were severe. This corresponded to a rate of 8.7 all-cause LRTI, 1.5 RSV-LRTI, and 0.8 severe RSV-LRTI per 100 infants per year, lower than the rates seen before the COVID-19 pandemic. Most RSV-LRTI cases occurred in infants 6 months or older, later than what was usually reported before the COVID-19 pandemic. While our findings likely do not reflect a standard RSV season due to the low virus circulation because of COVID-19 measures, they provide important information on RSV illness during the COVID-19 pandemic.

Lower respiratory tract illnesses (LRTIs) are a major cause of morbidity and mortality in children <5 years old, with respiratory syncytial virus (RSV) being a leading etiology [1, 2]. In regions with temperate climates, RSV causes yearly epidemics during autumn and winter months. In the tropics, RSV circulation is often highest during rainy seasons, with infections occurring throughout the year [3, 4]. RSV caused an estimated 33.0 million acute LRTIs in <5-year-olds in 2019 worldwide, one-fifth of which occurred in the first 6 months of life and >95% in low- and middle-income countries (LMICs) [5]. This resulted in an estimated 3.6 million hospital admissions, 26 300 in-hospital deaths, and 101 400 RSV-associated deaths in <5-year-olds (with almost half in <6-month-olds) [5].

During the first year of the coronavirus disease 2019 (COVID-19) pandemic, the number of infections with RSV and other seasonal respiratory viruses decreased dramatically, due to nonpharmaceutical interventions (NPIs) implemented to reduce the spread of COVID-19, such as lockdowns, physical distancing, reduced social mixing, mask mandates, and increased hand hygiene [6–13]. As these measures relaxed, off-season RSV outbreaks were seen [8, 13–17].

Country-specific estimates of the incidence of laboratory-confirmed RSV-LRTI and RSV-associated hospitalization in infants are scarce or outdated, especially in LMICs [18–20]. Accurate estimates of the RSV-LRTI burden would help plan efficacy trials of prophylactic interventions (eg, RSV vaccine candidates and monoclonal antibodies). They might also support policy decisions on implementing such interventions in LMICs [18–20].

Currently available RSV-LRTI incidence rates (IRs) for LMICs vary widely across studies [5, 21], partly due to differences in diagnostic methods, case definitions, and whether active or passive surveillance was used [20]. Standardization of surveillance methods and case definitions would support comparison of data across different countries. We performed a prospective, multicountry study in LMICs using reliable surveillance mechanisms and standardized case definitions for RSV-associated illnesses to better understand and quantify the RSV burden in infants in LMICs and help plan future RSV

vaccine efficacy trials. We estimated the incidence of all, severe, and very severe RSV-LRTI, RSV hospitalization, and all-cause LRTI in infants using World Health Organization (WHO) case definitions [20]. We also aimed to describe coinfections with other respiratory viruses and cord blood RSV-A and RSV-B neutralizing antibody levels among infants developing RSV-LRTI.

The study's primary objectives (frequency of pregnancy outcomes and pregnancy-related and neonatal events of interest) will be reported separately.

METHODS

Study Design and Participants

We conducted a prospective cohort study in 10 LMICs (Argentina, Bangladesh, Brazil, Colombia, Malaysia, Mexico, Panama, the Philippines, South Africa, and Thailand) from 30 May 2019 until 20 October 2021, which largely overlapped with the COVID-19 pandemic. We enrolled healthy pregnant women 18–45 years old, with uncomplicated pregnancies, and their live-born infants. Detailed inclusion and exclusion criteria are provided in the [Supplementary Materials](#).

Infants were followed up for 1 year with scheduled visits at birth, 42 days, 6 months, and 12 months of age, contacts for active and passive LRTI surveillance, and ad hoc visits to assess potential LRTIs ([Figure 1](#)). No interventional products were administered.

Patient Consent Statement

All participating women gave written or witnessed/thumbprinted informed consent before participation. Informed consent for infant participation was given by the mother (and father, if required by local regulations) or legally acceptable representative (LAR) at the same time as the consent for the mother's participation or within 21 days after the infant's birth. We conducted the study (ClinicalTrials.gov identifier NCT03614676) in accordance with the International Council for Harmonisation guidelines for Good Clinical Practice and followed the principles of the Declaration of Helsinki and applicable local guidelines. The study protocol and amendments (available at:




Figure 1. Study design and lower respiratory tract illness (LRTI) surveillance decision tree. ^aFor active contacts, site staff contacted the parents approximately every week during the respiratory syncytial virus (RSV) season and every month during interseason periods in countries with seasonal RSV transmission, and approximately every 2 weeks in countries with year-round RSV transmission. RSV seasonality by country is shown in Figure 2, and information on how seasons were determined is included in the Supplementary Materials. ^bFor passive contacts (which occurred throughout the year independently of RSV seasonality), parents contacted the site staff whenever the infant developed (new) symptoms of a respiratory tract illness (RTI), difficulty breathing, or wheezing; if the infant’s symptoms worsened; or if there was parental concern (ie, if the parent[s], legally acceptable representative[s], or designate[s] were concerned about the infant’s RTI or general health in the context of the RTI and intended to seek medical care). For both active and passive contacts, a protocol-guided phone script was used to ensure all required information was collected. ^cThe decision for scheduling a visit to assess a possible LRTI and procedures during the visit are explained in the “decision tree for LRTI visit.” Assessment visits were conducted by qualified site staff (ie, physicians, nurses, nurse practitioners, physician’s assistants) with documented medical training (ie, medical or nursing license). Abbreviations: COVID-19, coronavirus disease 2019; LRTI, lower respiratory tract illness; RR, respiratory rate; RSV, respiratory syncytial virus; SpO₂, blood oxygen saturation measured by pulse oximetry in room air, if feasible.

<https://www.gsk-studyregister.com/en/trial-details/?id=207636>) were approved by the relevant institutional review boards or independent ethics committees for each site (Supplementary Materials).

LRTI Surveillance

LRTI surveillance was done through active and passive contacts starting at birth and ending at the year 1 visit (Figure 1). In active contacts, site staff contacted the infant’s parent(s), LAR(s), or their designate(s) at regular intervals by phone calls, text message, or other means, depending on best local practice. In countries with seasonal RSV transmission (Figure 2; Supplementary Materials: “RSV Seasonality”), this was approximately weekly

during the RSV season and monthly during interseason periods. In countries with year-round RSV transmission (Figure 2), active contacts occurred approximately every 2 weeks. During these contacts, the site staff assessed whether the infant had developed (new) LRTI symptoms, that is, cough, runny nose, or blocked nose (respiratory tract illness [RTI] symptoms) together with difficulty breathing, wheezing, or parental concern (Figure 1). In passive contacts (which occurred throughout the year independently of the RSV season), the infant’s parent(s), LAR(s), or their designate(s) spontaneously contacted the site staff whenever the infant developed (new) RTI symptoms, difficulty breathing, or wheezing; if the infant’s symptoms worsened; or if there was parental concern (Figure 1). During

Table 1. Case Definitions for Respiratory Tract Illness and Lower Respiratory Tract Illness Based on Those Proposed by the World Health Organization Respiratory Syncytial Virus Vaccine Consultation Expert Group [20]

Variable	Case Definition
RSV-RTI	Runny nose or blocked nose or cough AND confirmed RSV infection ^a
RSV-LRTI	History of cough or difficulty breathing ^b AND SpO ₂ <95% ^c or RR increase ^d AND confirmed RSV infection ^a
Severe RSV-LRTI	Meeting the case definition of RSV-LRTI AND SpO ₂ <93% ^c or lower chest wall indrawing
Very severe RSV-LRTI	Meeting the case definition of RSV-LRTI AND SpO ₂ <90% ^c or inability to feed or failure to respond/being unconscious
RSV hospitalization	Confirmed RSV infection ^a AND hospitalized for acute medical condition ^e
All-cause RTI	Runny nose or blocked nose or cough
All-cause LRTI	History of cough or difficulty breathing ^b AND SpO ₂ <95% ^c or RR increase ^d

Abbreviations: LRTI, lower respiratory tract illness; RR, respiratory rate; RSV, respiratory syncytial virus; RTI, respiratory tract illness; SpO₂, blood oxygen saturation measured by pulse oximetry.

^aRSV infection confirmed on nasal swab positive for RSV-A or RSV-B subtypes by quantitative reverse-transcription polymerase chain reaction.

^bBased on history reported by parent(s)/legally acceptable representatives; difficulty breathing as evident from, eg, signs of wheezing or stridor, tachypnea, flaring of nostrils, chest indrawing, or apnea.

^cFor SpO₂, the lowest monitored value was used. At high altitudes (>2500 m), SpO₂ <92% for LRTI, <90% for severe LRTI, and <87% for very severe LRTI.

^dRR increase was defined as >60 breaths/minute (<2 months of age), >50 breaths/minute (2–11 months of age), and >40 breaths/minute (12–24 months of age).

^eHospitalization was defined as admission for observation or treatment based on the judgment of a healthcare provider.

each surveillance contact, the staff reminded the parent(s), LAR(s), or designate(s) to report any future new/worsening RTI symptoms.

If there was difficulty breathing, wheezing, or parental concern, a visit to assess potential LRTI was conducted (Figure 1). During this visit, the site staff evaluated clinical signs and symptoms of the RTI and recorded the infant's temperature, respiratory rate, blood oxygen saturation, signs of difficulty breathing (including wheezing, tachypnea, nasal flaring, chest indrawing, or apnea), and possible presence of COVID-19 infection (Figure 1). Case definitions for any, severe, and very severe RSV-LRTI, RSV hospitalization, and all-cause LRTI were based on those proposed by the WHO RSV Vaccine Consultation Expert Group [20] (Table 1), with LRTI defined by history of cough or difficulty breathing, and blood oxygen saturation <95% or increased respiratory rate; chest X-rays were not required.

A nasal swab (Supplementary Materials) was taken for detection of the 2 RSV subtypes (RSV-A and RSV-B) using quantitative reverse-transcription polymerase chain reaction (PCR) (at GSK or a designated laboratory), as previously described [22]. RSV-positive swabs (defined as 304 copies/mL for RSV-A and 475 copies/mL for RSV-B) were also tested for

the presence of 17 other respiratory viral types and subtypes using multiplex PCR (Allplex Respiratory Panel [Seegene] or similar). RSV-negative swabs were not tested for other viruses.

The infant's parent(s), LAR(s), or designate(s) recorded RTI symptoms (including start and end dates) in paper diary cards (Supplementary Materials). Appropriate clinical care was provided at the study site or another treating clinical facility per local standard of care. If an infant was admitted to the hospital for an acute medical event and RSV infection was suspected (based on the RTI case definition), a nasal swab was collected (if possible) and tested for RSV-A/B at GSK or a designated laboratory. As the study took place during the COVID-19 pandemic, special measures were implemented (Supplementary Materials).

Cord Blood Antibodies

Approximately 5–10 mL of cord blood was collected at delivery, and serum RSV-A and RSV-B neutralizing antibodies were measured using an in-house neutralization assay (Supplementary Materials).

Statistical Analyses

We aimed to enroll approximately 2300 pregnant women and their infants (200–300 per country). Sample size calculations were based on the primary objectives (reported elsewhere). Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, North Carolina). All analyses were performed on infants who met all eligibility criteria up to the time of their censoring (study completion or drop-out) with at least 1 timepoint evaluation and born to enrolled mothers who met all eligibility criteria up to the time of their censoring.

Incidence analyses for RSV-LRTI, severe and very severe RSV-LRTI, RSV hospitalizations, and all-cause LRTI were performed overall, by country, by age stratum (0–2, 0–5, and 0–11 months), and by 1-month intervals. IRs for first episodes (expressed per 100 person-years [PY]) were calculated with exact 95% confidence intervals (CIs) by dividing the number of infants with a first episode during the follow-up by the total PY. Proportions affected were calculated with exact 95% CIs as the number of infants with at least 1 episode within an age interval (0–2, 0–5, and 0–11 months) over the total number of infants at the start of the age interval. Incidence proportions were calculated with exact 95% CIs as the number of infants with a first episode within an age interval (monthly) over the population at risk at the start of the age interval. The person-time at risk for an event was calculated as the time between the date of birth and the end of the at-risk period or the earliest of the following: first diagnosis of the event, first birthday, death, or last follow-up.

Percentages of infants with RSV-LRTI coinfecting with other respiratory viruses were calculated with exact 95% CIs and geometric mean titers (GMTs) for RSV-A and RSV-B neutralizing antibodies with 95% CIs.

Missing data were not replaced.




Figure 2. Participant flow diagram. Respiratory syncytial virus (RSV) seasons were defined as described before the coronavirus disease 2019 pandemic and are shown per country and study site (if the transmission season varied for the different sites). Months with RSV transmission for 1 calendar year (from January [J] to December [D]) are highlighted. Information on how the seasons were determined for each site is provided in the [Supplementary Materials](#). Abbreviations: RSV, respiratory syncytial virus; SAE, serious adverse event.

RESULTS

Participants

In total, 2181 infants were enrolled and 2094 were included in the analysis, of whom 1939 completed the study. The main reason for withdrawal was loss to follow-up (Figure 2).

The mean gestational age of enrolled infants at birth was 38.5 weeks, and 141 infants (6.7%) were born prematurely (<37 weeks' gestation). Nearly all infants (97.7%) were breastfed (mean duration, 9.9 months) (Table 2). Demographic characteristics were similar across the different countries (Supplementary Table 1).

Of all enrolled infants, 49.3% were born during the RSV transmission season (with seasons as described before the COVID-19 pandemic; Figure 2), but this proportion varied widely between countries (from 7.0% in Thailand to 100% in Malaysia and the Philippines) depending on the individual country's RSV seasonality (Supplementary Table 1).

Overall Incidence of RSV-LRTI, RSV Hospitalization, and All-Cause LRTI

Among the 2094 infants included in the analysis, 32 experienced an RSV-LRTI during the 1-year follow-up. No recurrent episodes were reported. Eight infants had an episode during

their first 6 months of life; 24 had an episode thereafter (Figure 3). The proportion of infants affected by RSV-LRTI was low (0.2%, 0.4%, and 1.5% for infants aged 0–2, 0–5, and 0–11 months, respectively) (Table 3). The overall IR of first RSV-LRTI episode was 1.0/100 PY (95% CI, .3–2.3) in 0- to 2-month-olds, 0.8/100 PY (95% CI, .3–1.5) in 0- to 5-month-olds, and 1.6/100 PY (95% CI, 1.1–2.2) in 0- to 11-month-olds (Table 3; Figure 4).

Seventeen infants had a severe RSV-LRTI: 5 infants in the first 6 months and 12 thereafter. The proportions of infants affected by at least 1 severe RSV-LRTI were 0.1%, 0.2%, and 0.8% for those aged 0–2, 0–5, and 0–11 months, respectively (Table 3). The overall IR of first severe RSV-LRTI episode was 0.4/100 PY (95% CI, .0–1.4) in 0- to 2-month-olds, 0.5/100 PY (95% CI, .2–1.1) in 0- to 5-month-olds, and 0.8/100 PY (95% CI, .5–1.3) in 0- to 11-month-olds (Table 3; Figure 4).

None of the infants experienced a very severe RSV-LRTI.

Seven infants were hospitalized with RSV. The proportions of infants affected by RSV hospitalization among those aged 0–2, 0–5, and 0–11 months were 0.1%, 0.2%, and 0.3%, respectively (Table 3). The IR of first-time RSV hospitalization was comparable in the 3 age strata: 0.4 (95% CI, .0–1.4), 0.4 (95%

Table 2. Baseline Characteristics of Participating Infants (Enrolled Set)

Characteristic	Overall (N = 2181)
Gestational age at birth, wk	
Mean (SD)	38.5 (1.7)
Median (range)	39.0 (27–43)
Missing, No.	11
Sex	
Female	1049 (48.1)
Male	1132 (51.9)
Born in RSV transmission season^a	
Yes	1076 (49.3)
No	1105 (50.7)
Length, cm	
Mean (SD)	49.2 (2.7)
Missing, No.	59
Birth weight, kg	
Mean (SD)	3.1 (0.5)
Missing, No.	29
5-min Apgar score	
Mean (SD)	9.4 (0.8)
Median	9.0
Missing, No.	172
Breastfeeding	
Yes	2131 (97.7)
No	12 (0.6)
Missing, No.	38
Mean duration (SD), mo	9.9 (3.8)

Unless otherwise indicated, data are presented as number (%) of infants in a given category/total number of infants in the enrolled set.

Abbreviations: RSV, respiratory syncytial virus; SD, standard deviation.

^aRSV transmission season depended on the country and the study site and could include autumn/winter months or rainy seasons or be year-round. For the study, seasons were defined as described before the coronavirus disease 2019 (COVID-19) pandemic (Figure 2; Supplementary Materials: “RSV seasonality”). However, RSV seasonality was impacted by the COVID-19 pandemic [6–8].

CI, .1–1.0), and 0.3 (95% CI, .1–.7) per 100 PY (Table 3; Figure 4).

In total, 168 infants experienced at least 1 all-cause LRTI, most (117) of whom had a first episode during their first 6 months of life (Figure 3). There were 37 recurrent all-cause LRTI episodes. The proportions affected by at least 1 all-cause LRTI were 2.6%, 5.6%, and 8.0% for infants aged 0–2, 0–5, and 0–11 months, respectively (Table 3). IRs of first all-cause LRTI episode were 10.7/100 PY (95% CI, 8.1–14.0) in 0- to 2-month-olds, 11.7/100 PY (95% CI, 9.6–14.0) in 0- to 5-month-olds, and 8.7/100 PY (95% CI, 7.5–10.2) in 0- to 11-month-olds (Table 3; Figure 4). Overall, 19.0% of first all-cause LRTI episodes were positive for RSV.

Monthly incidence proportions were relatively homogeneous during the first year of life (0.0%–0.3% for RSV-LRTI, 0.0%–0.2% for severe RSV-LRTI, 0.0%–0.05% for RSV hospitalizations, and 0.1%–1.3% for all-cause LRTI).

Incidence of RSV-LRTI, RSV Hospitalization, and All-Cause LRTI by Country

No RSV-LRTI cases were reported in infants in Malaysia, the Philippines, Argentina, Mexico, or Panama. Of the 32

RSV-LRTI episodes in 0- to 11-month-olds, 15 were reported in Bangladesh (of which 8 were severe), 7 in Colombia (3 severe), 6 in South Africa (4 severe), and 2 each in Brazil and Thailand (1 severe each). In Bangladesh and Thailand, all cases were reported after the first 6 months of life, whereas in the other countries, cases were spread more uniformly in the first and second 6 months (Figure 3). The IRs of first RSV-LRTI and first severe RSV-LRTI episode during the first year of life were highest in Bangladesh (8.3/100 PY for RSV-LRTI, 4.4/100 PY for severe RSV-LRTI) and varied across the other countries with reported cases (0.8–2.9/100 PY for any RSV-LRTI; 0.4–1.2/100 PY for severe RSV-LRTI) (Figure 4; Supplementary Table 2).


There were no RSV hospitalizations among infants in Bangladesh, the Philippines, South Africa, Argentina, Mexico, or Panama. In the other countries, IRs for first RSV hospitalizations in 0- to 11-month-olds were 0.6–1.2/100 PY (Figure 4; Supplementary Table 2).

All-cause LRTI cases were reported in all countries except Malaysia. Of the 168 first all-cause LRTIs, 72 occurred in infants in Bangladesh (proportion of infants affected: 37.9%), 33 in Argentina (11.7%), 21 in South Africa (5.6%), 16 in Colombia (6.3%), 12 in Brazil (6.6%), 5 each in Thailand and Mexico (2.0% and 5.3%), 3 in the Philippines (1.3%), and 1 in Panama (1.6%). In most countries, more cases were reported in the first 6 months of life (Figure 3; Supplementary Table 2). The highest IR for first all-cause LRTI episode in 0- to 11-month-olds was reported for Bangladesh (49.6/100 PY). IRs varied between 1.3 and 13.1/100 PY for the other countries that had reported cases (Figure 4; Supplementary Table 2). The proportion of first all-cause LRTI episodes that tested positive for RSV ranged from 0.0% to 43.8% across countries.

Frequency of Symptoms in Infants With RSV-LRTI and All-Cause LRTI

Among the 32 infants with RSV-LRTI, the most frequently reported symptoms were cough (100%), runny nose (81.3%), wheezing (56.3%), and blocked nose (50.0%) (Supplementary Table 3). Among the 168 infants with all-cause LRTI, the most common symptoms during their first episode were cough (92.9%), runny nose (77.4%), blocked nose (65.5%), and wheezing (39.3%) (Supplementary Table 3). Similar frequencies of symptoms were reported during the 37 recurrent episodes (Supplementary Table 3). When empirically comparing all RSV-LRTI with all RSV-negative LRTI cases, the frequency of the different symptoms was generally similar, although blocked nose tended to be more common in RSV-negative LRTI (69.2%) than in RSV-LRTI (50.0%), while the opposite was seen for wheezing (39.5% in RSV-negative LRTI vs 56.3% in RSV-LRTI) and fever (14.0% in RSV-negative LRTI vs 25.0% in RSV-LRTI) (Supplementary Table 3).

A RSV-LRTI



B All-cause LRTI




Figure 3. Number of respiratory syncytial virus (RSV)-associated lower respiratory tract illness (LRTI) cases (A) and all-cause LRTI cases (B) by country and month of life. LRTI is based on the World Health Organization case definition. The n values indicate the total number of infants in the analysis for each country.

Coinfections of RSV-LRTI With Other Respiratory Viruses

In total, 33 swabs were available from the 32 infants with RSV-LRTI and 16 swabs from the 17 infants with severe RSV-LRTI. Viral coinfection was detected in 13 (39.4%) and 6 (37.5%) of these swabs, respectively, with rhinovirus identified most frequently (Supplementary Table 4).

Neutralizing RSV Antibodies in Cord Blood of Infants Developing RSV-LRTI

The cord blood samples of all infants, including the 8 infants who developed RSV-LRTI during their first 6 months of life, were seropositive for both RSV-A and RSV-B neutralizing antibodies. GMTs among these 8 infants were 478.2 estimated dilution 60 (ED_{60}) (95% CI, 215.9–1059.1) for RSV-A and 697.5 ED_{60} (95% CI, 332.3–1464.3) for RSV-B. Among the 5 infants

with RSV-LRTI in the first 3 months of life, GMTs were 322.0 ED_{60} (95% CI, 124.7–831.4) for RSV-A and 543.9 ED_{60} (95% CI, 162.2–1823.4) for RSV-B. This compared to GMTs of 751.5 ED_{60} (95% CI, 724.7–779.4) for RSV-A and 1221.1 ED_{60} (95% CI, 1172.2–1272.1) for RSV-B across all cord blood samples.

The association between cord blood antibodies and RSV-LRTI could not be analyzed because of the low number of RSV-LRTI cases.

COVID-19 Cases

Throughout the study, 116 COVID-19 cases were diagnosed in 98 (4.5%) enrolled infants. Fifteen infants had multiple COVID-19 diagnoses. Most cases were reported in Brazil (47

Table 3. Incidence Rates of First Episodes of Respiratory Syncytial Virus (RSV)–Associated Lower Respiratory Tract Illness (LRTI), Severe RSV-LRTI, RSV Hospitalization, and All-Cause LRTI and Proportions Affected by at Least 1 Episode, Overall by Age Interval

Outcome and Age Group	No. of Infants With a First Episode	Overall (N = 2094)		
		Total PY	Incidence Rate (95% CI), per 100 PY	Proportion Affected, % (95% CI)
RSV-LRTI				
0–2 mo	5	516.7	1.0 (.3–2.3)	0.2 (.1–0.6)
0–5 mo	8	1029.7	0.8 (.3–1.5)	0.4 (.2–.8)
0–11 mo	32	2013.1	1.6 (1.1–2.2)	1.5 (1.0–2.2)
Severe RSV-LRTI				
0–2 mo	2	517.1	0.4 (.0–1.4)	0.1 (.0–.3)
0–5 mo	5	1030.8	0.5 (.2–1.1)	0.2 (.1–.6)
0–11 mo	17	2018.7	0.8 (.5–1.3)	0.8 (.5–1.3)
RSV hospitalization				
0–2 mo	2	516.9	0.4 (.0–1.4)	0.1 (.0–.3)
0–5 mo	4	1030.7	0.4 (.1–1.0)	0.2 (.1–.5)
0–11 mo	7	2022.6	0.3 (.1–.7)	0.3 (.1–.7)
All-cause LRTI				
0–2 mo	55	511.8	10.7 (8.1–14.0)	2.6 (2.0–3.4)
0–5 mo	117	1004.3	11.7 (9.6–14.0)	5.6 (4.6–6.7)
0–11 mo	168	1924.6	8.7 (7.5–10.2)	8.0 (6.9–9.3)

Abbreviations: CI, confidence interval; LRTI, lower respiratory tract illness based on the World Health Organization case definition; PY, person-years; RSV, respiratory syncytial virus.

cases in 39 infants) and Panama (20 cases in 15 infants) (Supplementary Table 5). Among the 116 reported COVID-19 diagnoses, 16 (13.8%) were confirmed, 24 (20.7%) were probable, and 76 (65.5%) were suspected cases; 108 cases (93.1%) were symptomatic. Of the 16 confirmed COVID-19 cases, 2 had an LRTI (RSV negative).

DISCUSSION

This prospective study conducted during the COVID-19 pandemic in 10 LMICs showed a relatively low incidence of RSV-LRTI (1.6/100 PY), severe RSV-LRTI (0.8/100 PY), and RSV hospitalization (0.3/100-PY) and an absence of very severe RSV-LRTI in infants during their first year of life. IRs for both RSV-LRTI and severe RSV-LRTI varied widely across countries, with the highest rates in Bangladesh and no cases in Malaysia, the Philippines, Argentina, Mexico, and Panama. Across different countries, RSV-LRTI cases were either reported exclusively after the first 6 months of life or relatively uniformly in the first and second 6 months.

Our estimates were lower than those reported previously [5, 21–24]. A global meta-analysis based on pre-COVID-19 data estimated RSV-LRTI IRs in infants 0–12 months of 7.8/100 PY in low-income, 11.1/100 PY in lower-middle-income, and 10.9/100 PY in upper-middle-income countries [5]. In a study similar to ours conducted from 2013 to 2017, the IRs per 100 PY of RSV-LRTI during the first year of life were higher than those observed in the current study for the same countries (Argentina: 14.0 vs 0.0 in the current study; Bangladesh: 20.3 vs 8.3; South Africa: 3.1 vs 1.7; and Thailand: 2.5 vs 0.8) [24].

The lower IRs in our study are likely explained by NPIs (instated to curb the spread of COVID-19) reducing the circulation of RSV and other respiratory viruses. This was shown in other studies, including in several of the countries in our study [6–10, 25–29]. The impact of NPIs on RSV circulation and seasonality may also explain why in some countries, all RSV-LRTI cases were observed in infants ≥ 6 months old, while previous studies showed that the greatest burden was during the first 6 months of life [5, 21, 22]. This is consistent with other studies showing that RSV-LRTI cases occurred at an older age during the COVID-19 pandemic compared to before [12, 17]. Delays in the RSV season because of COVID-19–related NPIs and subsequent relaxation of NPIs may have resulted in an expanded group of older RSV-naïve infants [30].

IRs for all-cause LRTI were also lower in our study compared to those reported before the COVID-19 pandemic [24, 31–33]. In the study similar to ours conducted from 2013 to 2017, all-cause LRTI IRs per 100 PY in the first year of life were 40.2 in Argentina (vs 13.1 in our study), 74.0 in Bangladesh (vs 49.6), 14.5 in South Africa (vs 6.1), and 8.1 in Thailand (vs 2.0) [24]. Lower all-cause LRTI rates during versus before COVID-19 have been observed previously [25, 34]. In our study, countries with a higher incidence of all-cause LRTI had a higher incidence of RSV-LRTI. Argentina was an exception, with the 1-but-highest incidence of all-cause LRTI but no RSV-LRTI cases. Contrary to RSV infections, we found that most first episodes of all-cause LRTI occurred during the first 6 months of life. It was shown previously that not all respiratory pathogens were controlled to the same extent by NPIs, possibly due to differences in viral tropism, mode of transmission, sensitivity to




Figure 4. Incidence rates of first episode of respiratory syncytial virus (RSV)-associated lower respiratory tract illness (LRTI) (A), severe RSV-LRTI (B), RSV hospitalization (C), and all-cause LRTI (D) by age interval, overall and for each country. Error bars indicate 95% confidence intervals. LRTI is based on the World Health Organization case definition.

disinfectants, and virus–virus interactions [8–10, 35, 36]. Some of the LRTIs may have been caused by COVID-19.

Rhinovirus was identified most often as a second virus in infants with RSV-LRTI, in line with previous studies analyzing viral coinfections in infants and young children with LRTI [37–40]. Rhinovirus was also 1 of the respiratory viruses that was least affected by NPIs and became predominant in several countries during 2020–2021 [8, 10, 35, 36].

Comparing the clinical features of RSV-LRTI cases between our study and other studies is challenging because of differences in age, settings, study periods, and geographic locations [41–46]. However, despite variability in the frequencies of symptoms, the range of symptoms associated with RSV-LRTI was similar across studies, with cough and runny nose being the most common and a substantial proportion of infants presenting wheezing.

While we could not formally analyze the association between cord blood antibodies and RSV-LRTI because of the low number of RSV-LRTI cases, RSV neutralizing antibody GMTs in cord blood of infants who developed RSV-LRTI were lower than in the overall study population, in line with previous observations showing that RSV neutralizing antibodies at birth predict protection against RSV illness [47].

Because our study overlapped with the first years of the COVID-19 pandemic, when NPIs impacted RSV circulation and seasonality, our findings most likely do not reflect a standard RSV season and are applicable only to the countries/regions included in the study in the context of a global pandemic. The small number of cases prevented further subgroup analyses. Another limitation is that our results may not reflect incidences in a high-risk population because the number of high-risk infants was low.

Strengths of our study include the use of active and passive surveillance and standardized case definitions and its focus on LMICs, where the RSV burden is the highest [5], incidence data are sparse, and surveillance programs and the application of harmonized case definitions are often lacking [18, 20].

In conclusion, the RSV-LRTI IRs in the first year of life reported in our study were lower than what was reported before the COVID-19 pandemic, likely due to the impact of NPIs on viral circulation.

Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. We are grateful to all participants, their caregivers, study nurses, coordinators, investigators, and other study team members. Medical writing (by Natalie Deneff), design, and coordination support were provided by Akkodis Belgium c/o GSK.

Author contributions. R. L., U. D. A. N., A. G., P. D., K. Z., C. E. R., B. M., T. D. L., K. A., O. H., G. D. S., A. N. T., and Y. P. were involved in the conception or the design of the study. M. F. R., A. C., M. D. B., R. L., U. D. A. N., A. G., M. F. L., M. T. R. B., J. C., A. F., P. D., K. Z., M. M. M. P., J. P., A. V. S., C. M. C., J. A. V. P., D. A. A. F., C. E. R., E. L. M., B. M., J. N. R. N., A. S. G., L. S., C. M. F. L., R. S., S. W. T., E. C. D. S., I. H. T., C. d. C. F. A., J. C. T., I. A. d. R., O. R., J. B. V. M., S. K., S. F., K. A., M. M., T. P., L. A., K. C., E. Y., G. D. S., J. H. K., A. N. T., and Y. P. participated in the collection or generation of the study data. M. F. R., A. C., M. D. B., R. L., U. D. A. N., A. G., M. F. L., M. T. R. B., J. C., A. F., P. D., K. Z., M. M. M. P., J. P., A. V. S., C. M. C., C. E. R., E. L. M., B. M., J. N. R. N., A. S. G., L. S., C. M. F. L., R. S., S. W. T., E. C. D. S., I. H. T., C. d. C. F. A., J. C. T., I. A. d. R., O. R., J. B. V. M., S. K., S. F., K. A., M. M., T. P., L. A., K. C., E. Y., G. D. S., J. H. K., Y. P., and A. A. performed the study. A. C., M. D. B., R. L., U. D. A. N., A. G., M. T. R. B., J. C., A. F., P. D., K. Z., J. P., A. V. S., J. N. R. N., A. S. G., I. H. T., I. A. d. R., E. Y., Y. P., and A. A. contributed to the study with materials/analysis tools. R. L., A. G., P. D., K. Z., J. N. R. N., J. C. T., I. A. d. R., K. C., E. Y., G. D. S., J. H. K., S. P., A. N. T., Y. P., and A. A. were involved in the analysis or interpretation of the data. All authors approved the manuscript.

Data availability. Study data and documents can be requested for further research from www.clinicalstudydatarequest.com.

Financial support. This work was supported by GlaxoSmithKline Biologicals SA.

Potential conflicts of interest. J. H. K., A. N. T., E. Y., O. H., Y. P., and G. D. S. were employees of GSK when the study was designed, initiated, or conducted. J. H. K., A. N. T., E. Y., O. H., and G. D. S. declare they hold or held shares in GSK as part of their remuneration. A. A. and S. P. work for Keyrus Life Science on behalf of GSK. C. d. C. F. A. received payment from GSK for participation in the study, patient consultations, and ultrasounds. E. L. M. declares research grants from GSK, SP, Janssen, MSD, and the World Health Organization. T. P. received research grants from GSK through her institution. C. M. F. L. received consulting fees and payment for travel expenses for an investigator meeting from GSK and reports payment by GSK to Clinical Research Malaysia. A. V. S. declares research grant from GSK and grants or contracts from MSD, AstraZeneca, Esperion, Clover Biopharm, and F2G. L. S. declares payments from GSK to her institution as a research site for this study. R. S. reports study management and funding as principal investigator from GSK. J. B. V. M. declares payment received for a speaker's bureau for Wyeth Nutrition and participation as Chair of institutional review board, Chair of the Department of Health Single Joint Ethics review board, Chair of the Philippine Health Research Ethics Network, and member of the Philippine Health Technology Assessment Council. M. M. M. P. declares payment from GSK to her institution as a research site for this study. All other authors report no potential conflicts.

References

1. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis* 2018; 18:1191–210.
2. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; 392:1736–88.
3. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus—a comprehensive review. *Clin Rev Allergy Immunol* 2013; 45:331–79.
4. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. *J Infect Dis* 2018; 217:1356–64.
5. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet* 2022; 399:2047–64.
6. Di Mattia G, Nenna R, Mancino E, et al. During the COVID-19 pandemic where has respiratory syncytial virus gone? *Pediatr Pulmonol* 2021; 56:3106–9.
7. Gastaldi A, Donà D, Barbieri E, Giaquinto C, Bont LJ, Baraldi E. COVID-19 lesson for respiratory syncytial virus (RSV): hygiene works. *Children (Basel)* 2021; 8:1144.

8. Tang JW, Bialasiewicz S, Dwyer DE, et al. Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. *J Med Virol* **2021**; 93:4099–101.
9. Park KY, Seo S, Han J, Park JY. Respiratory virus surveillance in Canada during the COVID-19 pandemic: an epidemiological analysis of the effectiveness of pandemic-related public health measures in reducing seasonal respiratory viruses test positivity. *PLoS One* **2021**; 16:e0253451.
10. Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States, 2020–2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:1013–9.
11. Yum S, Hong K, Sohn S, Kim J, Chun BC. Trends in viral respiratory infections during COVID-19 pandemic, South Korea. *Emerg Infect Dis* **2021**; 27:1685–8.
12. van Summeren J, Meijer A, Asplund G, et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? *Euro Surveill* **2021**; 26:2100639.
13. Oh K-B, Doherty TM, Vetter V, Bonanni P. Lifting non-pharmaceutical interventions following the COVID-19 pandemic—the quiet before the storm? *Expert Rev Vaccines* **2022**; 21:1541–53.
14. Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. *Pediatrics* **2021**; 148:e2021052089.
15. Eden J-S, Sikazwe C, Xie R, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. *Nat Commun* **2022**; 13:2884.
16. Ferrero F, Ossorio MF, Rial MJ. The return of RSV during the COVID-19 pandemic. *Pediatr Pulmonol* **2022**; 57:770–1.
17. Foley DA, Yeoh DK, Minney-Smith CA, et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. *Clin Infect Dis* **2021**; 73:e2829–30.
18. Carbonell-Estrany X, Rodgers-Gray BS, Paes B. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries. *Expert Rev Anti Infect Ther* **2021**; 19:419–41.
19. Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. *BMC Med* **2020**; 18:82.
20. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS; World Health Organization RSV Vaccine Consultation Expert Group. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23–24 March 2015. *Vaccine* **2016**; 34:190–7.
21. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet* **2017**; 390:946–58.
22. Langley JM, Bianco V, Domachowski JB, et al. Incidence of respiratory syncytial virus lower respiratory tract infections during the first 2 years of life: a prospective study across diverse global settings. *J Infect Dis* **2022**; 226:374–85.
23. Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. *Pediatr Pulmonol* **2017**; 52:556–69.
24. Englund JA, Cohen RA, Bianco V, et al. Evaluation of clinical case definitions for respiratory syncytial virus lower respiratory tract infection in young children. *J Pediatric Infect Dis Soc* **2023**; 12:273–81.
25. Mameli C, Picca M, Buzzetti R, et al. Incidence of acute respiratory infections in preschool children in an outpatient setting before and during Covid-19 pandemic in Lombardy Region, Italy. *Ital J Pediatr* **2022**; 48:18.
26. Tempia S, Walaza S, Bhiman JN, et al. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. *Euro Surveill* **2021**; 26:2001600.
27. Varela FH, Scotta MC, Polese-Bonato M, et al. Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: likely role of lower transmission in the community. *J Glob Health* **2021**; 11:05007.
28. Thongpan I, Vichaiwattana P, Vongpunsawad S, Poovorawan Y. Upsurge of human rhinovirus infection followed by a delayed seasonal respiratory syncytial virus infection in Thai children during the coronavirus pandemic. *Influenza Other Respir Viruses* **2021**; 15:711–20.
29. Dolores A, Stephanie G, Mercedes S NJ, Érica G, Mistchenko AS, Mariana V. RSV reemergence in Argentina since the SARS-CoV-2 pandemic. *J Clin Virol* **2022**; 149:105126.
30. Koltai M, Krauer F, Hodgson D, et al. Determinants of RSV epidemiology following suppression through pandemic contact restrictions. *Epidemics* **2022**; 40:100614.
31. Borrero I, Fajardo L, Bedoya A, Zea A, Carmona F, de Borrero MF. Acute respiratory tract infections among a birth cohort of children from Cali, Colombia, who were studied through 17 months of age. *Rev Infect Dis* **1990**; 12(Suppl 8):S950–6.
32. MacGinty R, Lesosky M, Barnett W, et al. Maternal psychosocial risk factors and lower respiratory tract infection (LRTI) during infancy in a South African birth cohort. *PLoS One* **2019**; 14:e0226144.
33. Otani K, Saito M, Okamoto M, et al. Incidence of lower respiratory tract infection and associated viruses in a birth cohort in the Philippines. *BMC Infect Dis* **2022**; 22:313.
34. Uppala R, Sitthikarnkha P, Niamsanit S, et al. Effect of the COVID-19 pandemic on lower respiratory tract infection determinants in Thai hospitalized children: National Data Analysis 2015–2020. *Trop Med Infect Dis* **2022**; 7:151.
35. Mansuy JM, Bourcier M, Trémeaux P, Dimeglio C, Izopet J. COVID-19 pandemic period, where are the seasonal viruses? *J Med Virol* **2021**; 93:4097–8.
36. Liu P, Xu M, Cao L, et al. Impact of COVID-19 pandemic on the prevalence of respiratory viruses in children with lower respiratory tract infections in China. *Virol J* **2021**; 18:159.
37. Cebeý-López M, Herberg J, Pardo-Seco J, et al. Viral co-infections in pediatric patients hospitalized with lower tract acute respiratory infections. *PLoS One* **2015**; 10:e0136526.
38. Mazur NI, Bont L, Cohen AL, et al. Severity of respiratory syncytial virus lower respiratory tract infection with viral coinfection in HIV-uninfected children. *Clin Infect Dis* **2017**; 64:443–50.
39. Ogunbayo AE, Mogotsi MT, Sondlane H, Nkwadipo KR, Sabiu S, Nyaga MM. Pathogen profile of children hospitalised with severe acute respiratory infections during COVID-19 pandemic in the Free State Province, South Africa. *Int J Environ Res Public Health* **2022**; 19:10418.
40. Yu X, Kou Y, Xia D, et al. Human respiratory syncytial virus in children with lower respiratory tract infections or influenza-like illness and its co-infection characteristics with viruses and atypical bacteria in Hangzhou, China. *J Clin Virol* **2015**; 69:1–6.
41. Bashir U, Alam MM, Sadia H, Zaidi SSZ, Kazi BM. Molecular characterization of circulating respiratory syncytial virus (RSV) genotypes in Gilgit Baltistan Province of Pakistan during 2011–2012 winter season. *PLoS One* **2013**; 8:e74018.
42. Kamata K, Thein KN, Di Ja L, et al. Clinical manifestations and outcome of viral acute lower respiratory infection in hospitalised children in Myanmar. *BMC Infect Dis* **2022**; 22:350.
43. Lamarão LM, Ramos FL, Mello WA, et al. Prevalence and clinical features of respiratory syncytial virus in children hospitalized for community-acquired pneumonia in northern Brazil. *BMC Infect Dis* **2012**; 12:119.
44. Mathisen M, Strand TA, Sharma BN, et al. Clinical presentation and severity of viral community-acquired pneumonia in young Nepalese children. *Pediatr Infect Dis J* **2010**; 29:e1–6.
45. Ng KF, Tan KK, Sam ZH, Ting GSS, Gan WY. Epidemiology, clinical characteristics, laboratory findings and severity of respiratory syncytial virus acute lower respiratory infection in Malaysian children, 2008–2013. *J Paediatr Child Health* **2017**; 53:399–407.
46. Oladokun R, Muloiwa R, Hsiao NY, Valley-Omar Z, Nuttall J, Eley B. Clinical characterisation and phylogeny of respiratory syncytial virus infection in hospitalised children at Red Cross War Memorial Children's Hospital, Cape Town. *BMC Infect Dis* **2016**; 16:236.
47. Buchwald AG, Graham BS, Traore A, et al. Respiratory syncytial virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life. *Clin Infect Dis* **2021**; 73:e4421–7.